抗肥満薬の世界市場:末梢作用型抗肥満薬、中枢作用型抗肥満薬...市場調査レポートについてご紹介

【英文タイトル】Global Anti-Obesity Drugs Market 2015-2019

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings
03.2.1 Product Profiles

04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05.Introduction

06.Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis

07.Rate of Incidence and Prevalence
07.1.1 US
07.1.2 Europe

08.Types of Obesity
08.1 Monogenic Obesity
08.2 Polygenic Obesity

09.Causes of Obesity
09.1 Unhealthy Eating Habits
09.2 Sedentary Lifestyle
09.3 Certain medications
09.4 Lack of Sleep
09.5 Pregnancy
09.6 Medical problems

10.Classification of Obesity

11.Market Segmentation by Drug Class
11.1 Peripherally Acting Anti-obesity Drugs
11.2 Centrally Acting Anti-obesity Drugs

12.Geographical Segmentation

13.Buying Criteria

14.Market Growth Drivers
14.1 Increase in Prevalence of Obesity
14.2 Increase in Sedentary Lifestyle
14.3 Significant Unmet Needs
14.4 Promising Pipeline and Upcoming Launches of New Drugs

15.Drivers and their Impact

16.Market Challenges
16.1 High Drug Development Costs
16.2 Adverse Side Effects
16.3 Alternative Treatments
16.4 Multiple Drug Recalls

17.Impact of Drivers and Challenges

18.Market Trends
18.1 Fierce Market Competition
18.2 Strict Regulations
18.3 Increase in Strategic Alliances

19.Trends and their Impact

20.Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2013
20.3 Other Prominent Vendors

21.Key Vendor Analysis
21.1 Arena Pharmaceuticals
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Geographical Segmentation
21.1.4 Business Strategy
21.1.5 Recent Developments
21.1.6 SWOT Analysis
21.2 F. Hoffmann-La Roche
21.2.1 Key Facts
21.2.2 Business Overview
21.2.3 Business Segmentation
21.2.4 Business Segmentation by Revenue 2012 and 2013
21.2.5 Geographical Segmentation by Revenue
21.2.6 Business Strategy
21.2.7 Key Information
21.2.8 SWOT Analysis
21.3 GlaxoSmithKline
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Business Segmentation
21.3.4 Business Segmentation by Revenue 2012 and 2013
21.3.5 Sales by Geography
21.3.6 Pipeline Products
21.3.7 Business Strategy
21.3.8 Key Information
21.3.9 SWOT Analysis
21.4 Orexigen Therapeutics
21.4.1 Business Overview
21.4.2 Business Strategy
21.4.3 Recent Developments
21.4.4 SWOT Analysis
21.5 Vivus
21.5.1 Key Facts
21.5.2 Business Overview
21.5.3 Business Segmentation by Revenue 2013
21.5.4 Business Segmentation by Revenue 2012 and 2013
21.5.5 Geographical Segmentation by Revenue 2013
21.5.6 Business Strategy
21.5.7 Recent Information
21.5.8 SWOT Analysis

22.Other Reports in this Series

[List of Exhibits]
Exhibit 1: Market Research Methodology
Exhibit 2: Global Anti-obesity Drugs Market 2013-2018 (US$ million)
Exhibit 3: US Prevalence of Adult Overweight and Obesity (NHANES 2011-2012)
Exhibit 4: US Prevalence of Childhood Overweight and Obesity (NHANES 2011-2012)
Exhibit 5: Types of Obesity
Exhibit 6: Causes of Obesity
Exhibit 7: Global Anti-obesity Drugs Market Segmentation by Drug Class
Exhibit 8: Global Anti-obesity Drugs Market by Geographical Segmentation 2014
Exhibit 9: Arena Pharmaceuticals: Geographical Segmentation
Exhibit 10: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
Exhibit 11: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
Exhibit 12: F. Hoffmann-La Roche: Revenue of Pharmaceuticals Division by Geography 2013
Exhibit 13: F. Hoffmann-La Roche: Revenue of Diagnostics Division by Geography 2013
Exhibit 14: GlaxoSmithKline: Business Segmentation 2013
Exhibit 15: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 16: GlaxoSmithKline: Sales by Geography 2013
Exhibit 17: GlaxoSmithKline: Pipeline Products 2013
Exhibit 18: Vivus: Business Segmentation by Revenue 2013
Exhibit 19: Vivus: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 20: Vivus: Geographical Segmentation by Revenue 2013


【レポート販売概要】

■ タイトル:抗肥満薬の世界市場:末梢作用型抗肥満薬、中枢作用型抗肥満薬
■ 英文:Global Anti-Obesity Drugs Market 2015-2019
■ 発行日:2014年11月26日
■ 調査会社:Technavio
■ 商品コード:IRTNTR4645
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。